Skip to main content
. 2013 Nov 22;105(1):126–133. doi: 10.1111/cas.12305

Figure 3.

Figure 3

Cancer-specific survival in 113 patients with undifferentiated-type carcinoma based on marker expression: (a) MUC5AC, (b) MUC6, (c) MUC2, and (d) CD10. For each marker, there was no significant difference between survival rates of patients whose tumors were positive or negative for the marker (MUC5AC, = 0.753; MUC6, P = 0.226; MUC2, P = 0.745; and CD10, P = 0.328).